Original Source(s)
FDA Expands Guselkumab Label in PsA
-
by Kathryn Wighton
May 29, 2026
Related Content
RA Outcomes Improved in KURAMA Cohort
Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.
May 22, 2026
-
4 min
JAK Monotherapy Shows Efficacy in RA Review
A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.
May 22, 2026
-
4 min
FDA Clears Golimumab Biosimilars
New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.
May 18, 2026
-
2 min
